Related Experiment Video

Updated: Jul 16, 2026

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model
10:40

Visualization and Analysis of Blood Flow and Oxygen Consumption in Hepatic Microcirculation: Application to an Acute Hepatitis Model

Published on: August 4, 2012

12.6K

Correlation of effective hepatic blood flow with liver pathology in patients with hepatitis B virus

Xin Shu1, Haixia Sun1, Xiaoan Yang1

  • 1Department of Infectious Diseases, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Liver Research
|February 17, 2025
PubMed

Insights

Effective hepatic blood flow (EHBF) decreases with liver disease progression. This study found EHBF correlates with liver pathology, showing potential for predicting inflammation and fibrosis in hepatitis B virus patients.

Area of Science:

  • Hepatology
  • Medical Diagnostics
  • Biomedical Engineering

Background:

  • Effective hepatic blood flow (EHBF) is a key indicator of liver health.
  • Progression of liver disease is associated with a decline in EHBF.
  • Accurate assessment of liver pathology is crucial for patient management.

Purpose of the Study:

  • To investigate the correlation between EHBF and liver pathology in patients with hepatitis B virus (HBV).
  • To explore the potential of EHBF measurements for predicting the degree of liver inflammation and fibrosis.

Main Methods:

  • Enrolled 207 HBV patients undergoing liver biopsy and indocyanine green (ICG) clearance tests.
  • Measured EHBF using ICG clearance and assessed liver histology via Scheuer scoring.
  • Collected demographic, biochemical, and FibroScan data for statistical analysis.

Main Results:

  • EHBF levels significantly decreased with increasing stages of liver inflammation and fibrosis (P < 0.01).
  • EHBF showed significant negative associations with liver enzymes and stiffness measurements (P < 0.05).
  • EHBF effectively differentiated patients with and without liver inflammation/fibrosis, with high diagnostic accuracy (AUROC up to 0.827 for inflammation).

Conclusions:

  • EHBF levels are significantly correlated with liver pathology in HBV patients.
  • EHBF serves as a reliable indicator of liver inflammation and fibrosis.
  • EHBF is particularly effective in identifying early-stage liver disease, especially in patients without overt inflammation or fibrosis.
Abstract

Keywords:
Effective hepatic blood flow (EHBF)Hepatitis B virus (HBV)Liver diseaseLiver fibrosisLiver inflammation

More Related Videos

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy07:10

Measurement of the Hepatic Venous Pressure Gradient and Transjugular Liver Biopsy

Published on: June 18, 2020

19.6K
Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection04:11

Author Spotlight: Advancements and Challenges in Hepatitis B Virus Detection

Published on: December 15, 2023

3.1K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow01:26

Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow

Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug binding...
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Cirrhosis II: Pathophysiology01:24

Cirrhosis II: Pathophysiology

Cirrhosis is a progressive chronic liver injury caused by prolonged inflammation, excessive fibrotic remodeling, and impaired regeneration. Over time, repeated hepatic insults disrupt the liver’s architecture and function, leading to reduced blood flow, impaired bile drainage, and diminished metabolic capacity.Pathophysiology of cirrhosisCirrhosis arises from three main responses to chronic liver damage: inflammation, immune activation, and hepatocyte death. These processes lead to structural...